Cardiac Allograft Vasculopathy: A Donor or Recipient Induced Pathology?

详细信息    查看全文

• 作者：Patricia van den Hoogen (1) (2)
  Manon M. H. Huibers (2)
  Joost P. G. Sluijter (1)
  Roel A. de Weger (2)
  
  1. Department of Cardiology ; Experimental Cardiology laboratory ; University Medical Centre Utrecht ; Utrecht ; The Netherlands
  2. Department of Pathology ; University Medical Center Utrecht ; Room H04.312 Heidelberglaan 100 ; PO Box 85500 ; 3508 GA ; Utrecht ; The Netherlands
  
• 关键词：Heart transplantation ; Cardiac allograft vasculopathy ; Donor cells ; Recipient cells ; Immune response ; Fibrosis ; Mismatch ; Circulating cells
• 刊名：Journal of Cardiovascular Translational Research
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：8
• 期：2
• 页码：106-116
• 全文大小：1,117 KB
• 参考文献：1. Behrendt, D, Ganz, P, Fang, J (2000) Cardiac allograft vasculopathy. Current Opinion in Cardiology 78229: pp. 10-16
  2. Lund, LH, Edwards, LB, Kucheryavaya, AY (2013) The registry of the international society for heart and lung transplantation: thirtieth official adult heart transplant report鈥?013; focus theme: age. Journal of Heart and Lung Transplantation 32: pp. 951-964 2013.08.006" target="_blank" title="It opens in new window">CrossRef
  3. Seki, A, Fishbein, MC (2014) Predicting the development of cardiac allograft vasculopathy. Cardiovascular Pathology.
  4. Suzuki, J, Ogawa, M, Hirata, Y (2012) Effects of immunoglobulin to prevent coronary allograft vasculopathy in heart transplantation. Expert Opinion on Therapeutic Targets 16: pp. 783-789 28222.2012.697555" target="_blank" title="It opens in new window">CrossRef
  5. Costello, J (2013) Mechanisms of chronic cardiac allograft rejection. Texas Heart Instrum 40: pp. 395-399
  6. Kobashigawa, J (2000) What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?. Current Controlled Trials in Cardiovascular Medicine 1: pp. 166-171 CrossRef
  7. Daly, KP, Seifert, ME, Chandraker, A (2013) VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. Journal of Heart and Lung Transplantation 32: pp. 120-128 2012.09.030" target="_blank" title="It opens in new window">CrossRef
  8. Lu, W, Palatnik, K, Fishbein, GA (2011) Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts. Journal of Heart and Lung Transplantation 30: pp. 1044-1050 2011.04.008" target="_blank" title="It opens in new window">CrossRef
  9. Pober, J.S., Jane-Wit, D., Qin, L., Tellides, G. (2014). Interacting Mechanisms in the Pathogenesis of Cardiac Allograft Vasculopathy. / Arterioscler Thromb Vasc Biol. 1609鈥?614. doi: 10.1161/ATVBAHA.114.302818.
  10. Mitchell, RN (2009) Graft vascular disease: immune response meets the vessel wall. Annual Review of Pathology 4: pp. 19-47 21806.151449" target="_blank" title="It opens in new window">CrossRef
  11. Kalache, S, Dinavahi, R, Pinney, S, Mehrotra, A, Madeleine, W, Cunningham, PSH (2011) Anti-cardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients. Journal of Immunology 187: pp. 1023-1030 CrossRef
  12. Huibers, MMH, Vink, A, Kaldeway, J (2014) Distinct phenotypes of cardiac allograft vasculopathy after heart transplantation: a histopathological study. Atherosclerosis 236: pp. 353-359 2014.07.016" target="_blank" title="It opens in new window">CrossRef
  13. Atkinson, C, Horsley, J, Rhind-Tutt, S (2004) Neointimal smooth muscle cells in human cardiac allograft coronary artery vasculopathy are of donor origin. Journal of Heart and Lung Transplantation 23: pp. 427-435 2498(03)00222-5" target="_blank" title="It opens in new window">CrossRef
  14. Ueta, H, Shi, C, Miyanari, N (2008) Systemic transmigration of allosensitizing donor dendritic cells to host secondary lymphoid organs after rat liver transplantation. Hepatology 47: pp. 1352-1362 2/hep.22161" target="_blank" title="It opens in new window">CrossRef
  15. Benatti, RD, Taylor, DO (2014) Evolving concepts and treatment strategies for cardiac allograft vasculopathy. Current Treatment Options Cardiovascular Medical 16: pp. 278 278-x" target="_blank" title="It opens in new window">CrossRef
  16. Simper, D, Wang, S, Deb, A (2003) Endothelial progenitor cells are decreased in blood of cardiac allograft patients with vasculopathy and endothelial cells of noncardiac origin are enriched in transplant atherosclerosis. Circulation 108: pp. 143-149 26.5D" target="_blank" title="It opens in new window">CrossRef
  17. Borthwick, LA, Parker, SM, Brougham, KA (2009) Epithelial to mesenchymal transition (EMT) and airway remodelling after human lung transplantation. Thorax 64: pp. 770-777 2008.104133" target="_blank" title="It opens in new window">CrossRef
  18. Eisen, H (2008) Heart transplantation: graft rejection basics. Johns Hopkins Advanced Studies in Medieval 8: pp. 174-181
  19. Colvin-Adams, M, Harcourt, N, Duprez, D (2013) Endothelial dysfunction and cardiac allograft vasculopathy. Journal of Cardiovascular Translational Research 6: pp. 263-277 2265-012-9414-3" target="_blank" title="It opens in new window">CrossRef
  20. Smyth, LA, Harker, N, Turnbull, W (2008) The relative efficiency of acquisition of MHC:peptide complexes and cross-presentation depends on dendritic cell type. Journal of Immunology 181: pp. 3212-3220 212" target="_blank" title="It opens in new window">CrossRef
  21. Dolan, BP, Gibbs, KD, Ostrand-Rosenberg, S (2006) Tumor-specific CD4+ T cells are activated by 鈥渃ross-dressed鈥?dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. Journal of Immunology 176: pp. 1447-1455 CrossRef
  22. Jones, ND, Maurik, A, Hara, M (1999) T-cell activation, proliferation, and memory after cardiac transplantation in vivo. Annals of Surgery 229: pp. 570-578 CrossRef
  23. Zhang, Q, Cecka, J, Gjertson, D, Ge, P (2011) HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation 91: pp. 1153-1158 2157d60" target="_blank" title="It opens in new window">CrossRef
  24. Angaswamy, N, Tiriveedhi, V, Sarma, NJ (2013) Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Human Immunology 74: pp. 1478-1485 2013.07.002" target="_blank" title="It opens in new window">CrossRef
  25. Nath, D, Basha, H, Mohanakumar, T (2010) Anti-human leukocyte antigen antibody induced autoimmunity: role in chronic rejection. Current Opin Organic 15: pp. 16-20 283342780" target="_blank" title="It opens in new window">CrossRef
  26. Hachem, RR (2009) Lung allograft rejection: diagnosis and management. Current Opinion in Organ Transplantation 14: pp. 477-482 2832fb981" target="_blank" title="It opens in new window">CrossRef
  27. Benichou, G, Alessandrini, A, Rachida-Sihem Charrad, DSW (2007) Induction of autoimmunity after allotransplantation. Frontiers in Bioscience 12: pp. 4362-4369 2741/2393" target="_blank" title="It opens in new window">CrossRef
  28. Rolls, HK, Kishimoto, K, Dong, VM (2002) T-cell response to cardiac myosin persists in the absence of an alloimmune response in recipients with chronic cardiac allograft rejection. Transplantation 74: pp. 1053-1057 200210150-00028" target="_blank" title="It opens in new window">CrossRef
  29. Weiss, MJ, Madsen, JC, Rosengard, BR, Allan, JS (2008) Mechanisms of chronic rejection in cardiothoracic transplantation. Frontiers in Bioscience 13: pp. 2980-2988 2741/2903" target="_blank" title="It opens in new window">CrossRef
  30. Fedoseyeva, EV, Kishimoto, K, Rolls, HK (2002) Modulation of tissue-specific immune response to cardiac myosin can prolong survival of allogeneic heart transplants. Journal of Immunology 169: pp. 1168-1174 CrossRef
  31. Nath, D, Angaswamy, N, Basha, H (2010) With and precede antibodies to MICA in antibody mediated rejection and cardiac allograft vasculopathy following human cardiac transplantation. Humain 71: pp. 1191-1196
  32. Bij, W, Speich, R (2001) Management of cytomegalovirus infection and disease after solid-organ transplantation. Clinical Infectious Diseases 33: pp. s32-s37 20902" target="_blank" title="It opens in new window">CrossRef
  33. Potena, L, Valantine, HA (2007) Cytomegalovirus-associated allograft rejection in heart transplant patients. Current Opinion in Infectious Diseases 20: pp. 425-431 28259c33b" target="_blank" title="It opens in new window">CrossRef
  34. Izawa, A, Ueno, T, Jurewicz, M (2007) Importance of donor- and recipient-derived selectins in cardiac allograft rejection. Journal of the American Society of Nephrology 18: pp. 2929-2936 2006111261" target="_blank" title="It opens in new window">CrossRef
  35. Saiki, T, Ezaki, T, Ogawa, M (2001) In vivo roles of donor and host dendritic cells in allogeneic immune response: cluster formation with host proliferating T cells. Journal of Leukocyte 69: pp. 705-712
  36. Halloran, P (1998) Non-immunologic tissue injury and stress in chronic allograft dysfunction. Graft 1: pp. 25-29
  37. Gourishankar, S, Halloran, PF (2002) Late deterioration of organ transplants: a problem in injury and homeostasis. Current Opinion in Immunology 14: pp. 576-583 2-7915(02)00386-2" target="_blank" title="It opens in new window">CrossRef
  38. Watts, RP, Thom, O, Fraser, JF (2013) Inflammatory signalling associated with brain dead organ donation: from brain injury to brain stem death and posttransplant ischaemia reperfusion injury organ injury: current concepts. Journal of Transplantation 2013: pp. 1-19 2013/521369" target="_blank" title="It opens in new window">CrossRef
  39. Gourishankar, S (2003) Donor tissue characteristics influence cadaver kidney transplant function and graft survival but not rejection. Journal of the American Society of Nephrology 14: pp. 493-499 2164.03115.B8" target="_blank" title="It opens in new window">CrossRef
  40. Hollenberg, SM, Klein, LW, Parrillo, JE (2015) Coronary endothelial dysfunction after heart cardiac death. Circulation 104: pp. 3091-3097 CrossRef
  41. Ueno, T, Tanaka, K, Jurewicz, M (2009) Divergent role of donor dendritic cells in rejection versus tolerance of allografts. Journal of the American Society of Nephrology 20: pp. 535-544 2008040377" target="_blank" title="It opens in new window">CrossRef
  42. Win, TS, Rehakova, S, Negus, MC (2009) Donor CD4 T cells contribute to cardiac allograft vasculopathy by providing help for autoantibody production. Circulation Heart Failure 2: pp. 361-369 27139" target="_blank" title="It opens in new window">CrossRef
  43. Larsen, C, Morris, P, Austyn, J (1990) Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. Journal of Experimental 171: pp. 307-314 CrossRef
  44. Starzl, T, Murase, N, Ildstad, S, Ricordi, C (1992) Cell migration, chimerism, and graft acceptance. Lancet 339: pp. 1579-1582 2)91840-5" target="_blank" title="It opens in new window">CrossRef
  45. Yang, J, Popoola, J, Khandwala, S (2008) Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation 117: pp. 660-669 25" target="_blank" title="It opens in new window">CrossRef
  46. Tanaka, K, Albin, MJ, Yuan, X (2007) PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. Journal of Immunology 179: pp. 5204-5210 204" target="_blank" title="It opens in new window">CrossRef
  47. Koskinen, PK, Lemstro, KB (1997) Adhesion molecule P-selectin and vascular cell adhesion molecule鈥? in enhanced heart allograft arteriosclerosis in the rat. Circulation 95: pp. 191-196 CrossRef
  48. Shreeniwas, R (1996) Adhesion molecules (E-selectin and ICAM-1) in pulmonary allograft rejection. CHEST 110: pp. 1143-1149 CrossRef
  49. Sarraj, B, Ye, J, Akl, AI (2014) Impaired selectin-dependent leukocyte recruitment induces T-cell exhaustion and prevents chronic allograft vasculopathy and rejection. Proceedings of the National Academy of Sciences of the United States of America.
  50. Khush, KK, Kubo, JT, Desai, M (2012) Influence of donor and recipient sex mismatch on heart transplant outcomes: analysis of the international society for heart and lung transplantation registry. Journal of Heart and Lung Transplantation 31: pp. 459-466 2012.02.005" target="_blank" title="It opens in new window">CrossRef
  51. Schlechta, B, Kocher, AA, Ofner, P (1999) Impact of gender mismatch on the outcome of heart transplantation. Transplantation Proceedings 31: pp. 3340-3342 CrossRef
  52. Mehra, MR (2000) Crossing the vasculopathy bridge from morphology to therapy: a single center experience. Journal of Heart and Lung Transplantation 19: pp. 522-528 2498(00)00116-9" target="_blank" title="It opens in new window">CrossRef
  53. Reed, RM, Netzer, G, Hunsicker, L, Mitchell, BD, Rajagopal, K, Scharf, SEM (2014) Cardiac size and sex-matching in heart transplantation: size matters in matters of sex and the heart. American Collegium Cardiology Foundations Heart Failure 2: pp. 73-83
  54. Zeier, M (2002) The effect of donor gender on graft survival. Journal of the American Society of Nephrology 13: pp. 2570-2576 CrossRef
  55. Welp, H, Spieker, T, Erren, M (2009) Sex mismatch in heart transplantation is associated with increased number of severe rejection episodes and shorter long-term survival. Transplantation Proceedings 41: pp. 2579-2584 2009.06.098" target="_blank" title="It opens in new window">CrossRef
  56. Tan, J, Wadia, P, Coram, M (2008) HY antibody development associates with acute rejection in female patients with male kidney transplants. Transplantation 86: pp. 75-81 2b9" target="_blank" title="It opens in new window">CrossRef
  57. Huibers, M, Jonge, N, Kuik, J (2011) Intimal fibrosis in human cardiac allograft vasculopathy. Transplant Immunology 25: pp. 124-132 2011.07.001" target="_blank" title="It opens in new window">CrossRef
  58. Rahmani, M, Cruz, RP, Granville, DJ, McManus, BM (2006) Allograft vasculopathy versus atherosclerosis. Circulation Research 99: pp. 801-815 246086.93555.f3" target="_blank" title="It opens in new window">CrossRef
  59. Zeng, Q, Ng, Y, Singh, T (2014) B cells mediate chronic allograft rejection independently of antibody production. Journal.
  60. Koning, E, Kuik, J, Wichen, DF (2007) 237: M2 macrophages: keyplayers in the fibro-proliferative response in cardiac allograft vasculopathy. Journal Heart Lung Transplantation 26: pp. S145 2006.11.255" target="_blank" title="It opens in new window">CrossRef
  61. Kitchens, WH, Chase, CM, Uehara, S (2007) Macrophage depletion suppresses cardiac allograft vasculopathy in mice. American Journal of Transplantation 7: pp. 2675-2682 2007.01997.x" target="_blank" title="It opens in new window">CrossRef
  62. Mantovani, A, Sica, A, Sozzani, S (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends in Immunology 25: pp. 677-686 2004.09.015" target="_blank" title="It opens in new window">CrossRef
  63. Quaini, F, Urbanek, K (2002) Chimerism of the transplanted heart. English Journal 346: pp. 5-15
  64. Hillebrands, J-L, Onuta, G, Rozing, J (2005) Role of progenitor cells in transplant arteriosclerosis. Trends in Cardiovascular Medicine 15: pp. 1-8 2004.10.002" target="_blank" title="It opens in new window">CrossRef
  65. Hillebrands, J-L, Klatter, FA, Rozing, J (2003) Origin of vascular smooth muscle cells and the role of circulating stem cells in transplant arteriosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 23: pp. 380-387 CrossRef
  66. D鈥橝lessandro, DA, Kajstura, J, Hosoda, T (2009) Progenitor cells from the explanted heart generate immunocompatible myocardium within the transplanted donor heart. Circulation Research 105: pp. 1128-1140 207266" target="_blank" title="It opens in new window">CrossRef
  67. Hill, J, Zalos, G (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. English Journal 348: pp. 593-600
  68. Sathya, CJ, Sheshgiri, R, Prodger, J (2010) Correlation between circulating endothelial progenitor cell function and allograft rejection in heart transplant patients. Transplant International 23: pp. 641-648 2-2277.2009.01043.x" target="_blank" title="It opens in new window">CrossRef
  69. Minami, E, Laflamme, MA, Saffitz, JE, Murry, CE (2005) Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart. Circulation 112: pp. 2951-2958
  70. Wu, GD, Nolta, JA, Jin, YS (2003) Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation 75: pp. 679 CrossRef
  71. Bittmann, I, Dose, T, Baretton, GB (2001) Cellular chimerism of the lung after transplantation. An interphase cytogenetic study. American Journal of Clinical Pathology 115: pp. 525-533 CrossRef
  72. Weger, RA, Verbrugge, I, Bruggink, AH (2008) Stem cell-derived cardiomyocytes after bone marrow and heart transplantation. Bone Marrow Transplantation 41: pp. 563-569 CrossRef
  73. Wu, GD, Tuan, T-L, Bowdish, ME (2003) Evidence for recipient derived fibroblast recruitment and activation during the development of chronic cardiac allograft rejection. Transplantation 76: pp. 609-614 2.37931.6D" target="_blank" title="It opens in new window">CrossRef
  74. Pichler, M, Rainer, PP, Schauer, S, Hoefler, G (2012) Cardiac fibrosis in human transplanted hearts is mainly driven by cells of intracardiac origin. Journal of the American College of Cardiology 59: pp. 1008-1016 2011.11.036" target="_blank" title="It opens in new window">CrossRef
  75. Salomon, R, Hughes, C (1991) Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. The American Journal 4: pp. 791-798
  76. Chen, P, Qin, L, Barnes, C (2012) FGF regulates TGF-尾 signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Reports 2: pp. 1684-1696 2012.10.021" target="_blank" title="It opens in new window">CrossRef
  77. Kovacic, JC, Mercader, N, Torres, M (2012) Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: from cardiovascular development to disease. Circulation 125: pp. 1795-1808 2" target="_blank" title="It opens in new window">CrossRef
  78. Gise, A, Pu, W (2012) Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. Circulation Research 110: pp. 1628-1645 259960" target="_blank" title="It opens in new window">CrossRef
  79. Piera-Velazquez, S, Jimenez, SA (2012) Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases. Fibrogenesis & Tissue Repair 5: pp. S7 CrossRef
  80. Vongwiwatana, A, Tasanarong, A, Rayner, DC (2005) Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. American Journal of Transplantation 5: pp. 1367-1374 2005.00843.x" target="_blank" title="It opens in new window">CrossRef
  81. Zeisberg, EM, Tarnavski, O, Zeisberg, M (2007) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nature Medicine 13: pp. 952-961 CrossRef
  82. Zhou, B, Pu, WT (2011) Epicardial epithelial-to-mesenchymal transition in injured heart. Journal of Cellular and Molecular Medicine 15: pp. 2781-2783 2-4934.2011.01450.x" target="_blank" title="It opens in new window">CrossRef
  83. Chen, S, Cheng, A, Mehta, K (2013) A review of telemedicine business models. Telemedicine Journal and E Health 19: pp. 287-297 2012.0172" target="_blank" title="It opens in new window">CrossRef
  84. Hernandez, JMDLT, Prada, JAV, Burgos, V (2009) Virtual histology intravascular ultrasound assessment of cardiac allograft vasculopathy from 1 to 20聽years after heart transplantation. Journal of Heart and Lung Transplantation 28: pp. 156-162 2008.11.915" target="_blank" title="It opens in new window">CrossRef
  85. Machuca, TN, Cypel, M (2014) Ex vivo lung perfusion. Journal Thoracic Diseases 6: pp. 1054-1062
  86. Cypel, M, Keshavjee, S (2015) Extending the donor pool: rehabilitation of poor organs. Thoracic Surgery Clinics 25: pp. 27-33 2014.09.002" target="_blank" title="It opens in new window">CrossRef
  87. Machuca, T.N., Cypel, M., Yeung, J.C., Bonato, R., Zamel, R., Chen, M., Azad, S, Hsin, M.K., Saito, T., Guan, Z., Waddell, TK., Liu, M.K.S. (2014). Protein Expression Profiling Predicts Graft Performance in Clinical Ex Vivo Lung Perfusion. / Ann. Surg.
  88. Wang, S-S (2008) Treatment and prophylaxis of cardiac allograft vasculopathy. Transplantation Proceedings 40: pp. 2609-2610 2008.08.073" target="_blank" title="It opens in new window">CrossRef
  89. Valantine, H (2004) Cardiac allograft vasculopathy after heart transplantation: risk factors and management. Journal of Heart and Lung Transplantation 23: pp. S187-S193 2004.03.009" target="_blank" title="It opens in new window">CrossRef
  90. Kobashigawa, JA (2004) Statins in solid organ transplantation: is there an immunosuppressive effect?. American Journal of Transplantation 4: pp. 1013-1018 2004.00475.x" target="_blank" title="It opens in new window">CrossRef
  91. Grigioni, F, Carigi, S, Potena, L (2006) Long-term safety and effectiveness of statins for heart transplant recipients in routine clinical practice. Transplantation Proceedings 38: pp. 1507-1510 2006.02.071" target="_blank" title="It opens in new window">CrossRef
  92. Segovia, J, G贸mez-Bueno, M, Alonso-Pulp贸n, L (2006) Treatment of allograft vasculopathy in heart transplantation. Expert Opinion on Pharmacotherapy 7: pp. 2369-2383 2369" target="_blank" title="It opens in new window">CrossRef
  93. Delgado, JF, Manito, N, Segovia, J (2009) The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. Transplantation Reviews 23: pp. 69-79 2009.01.002" target="_blank" title="It opens in new window">CrossRef
  94. Kuppahally, S, Al-Khaldi, A, Weisshaar, D (2006) Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. American Journal of Transplantation 6: pp. 986-992 2006.01282.x" target="_blank" title="It opens in new window">CrossRef
  95. Masetti, M, Potena, L, Nardozza, M (2013) Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice. American Journal of Transplantation 13: pp. 1207-1226 2208" target="_blank" title="It opens in new window">CrossRef
  96. Kobashigawa, J, Mancini, D, S酶rensen, K (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. New England Journal of Medicine 349: pp. 847-858 22171" target="_blank" title="It opens in new window">CrossRef
  
• 刊物主题：Cardiology; Human Genetics; Biomedical Engineering; Biomedicine general; Medicine/Public Health, general;
• 出版者：Springer US
• ISSN：1937-5395

文摘

Cardiac allograft vasculopathy (CAV) is one of the main causes of late-stage heart failure after heart transplantation. CAV is characterized by concentric luminal narrowing of the coronary arteries, but the exact pathogenesis of CAV is still not unraveled. Many researchers show evidence of an allogeneic immune response of the recipient, whereas others show contrasting results in which donor-derived cells induce an immune response against the graft. In addition, fibrosis of the neo-intima can be induced by recipient-derived circulating cells or donor-derived cells. In this review, both donor and recipient sides of the story are described to obtain better insight in the pathogenesis of CAV. Dual outcomes were found regarding the contribution of donor and recipient cells in the initiation of the immune response and the development of fibrosis during CAV. Future research could focus more on the potential synergistic interaction of donor and recipient cells leading to CAV.